Bamco Inc. NY increased its holdings in Cerus Corporation (NASDAQ:CERS) by 20.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 560,900 shares of the biotechnology company’s stock after acquiring an additional 96,600 shares during the period. Bamco Inc. NY owned approximately 0.51% of Cerus Corporation worth $1,408,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Elk Creek Partners LLC increased its stake in Cerus Corporation by 32.3% during the second quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock worth $14,406,000 after acquiring an additional 1,402,106 shares during the last quarter. ARK Investment Management LLC raised its position in Cerus Corporation by 126.5% in the second quarter. ARK Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock valued at $4,219,000 after purchasing an additional 938,647 shares during the period. Delta Lloyd Asset Management N.V. purchased a new stake in Cerus Corporation in the second quarter valued at $1,255,000. Point72 Asset Management L.P. purchased a new stake in Cerus Corporation in the first quarter valued at $1,828,000. Finally, Vanguard Group Inc. raised its position in Cerus Corporation by 7.9% in the first quarter. Vanguard Group Inc. now owns 4,708,427 shares of the biotechnology company’s stock valued at $20,952,000 after purchasing an additional 343,597 shares during the period. Institutional investors own 58.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bamco Inc. NY Has $1.41 Million Position in Cerus Corporation (CERS)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at

In related news, insider Laurence M. Corash purchased 92,796 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $2.45 per share, for a total transaction of $227,350.20. Following the acquisition, the insider now directly owns 1,375,711 shares in the company, valued at $3,370,491.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.40% of the company’s stock.

Shares of Cerus Corporation (NASDAQ CERS) opened at 2.87 on Tuesday. The firm’s market cap is $313.22 million. The company has a 50-day moving average of $2.57 and a 200 day moving average of $2.94. Cerus Corporation has a 12-month low of $1.93 and a 12-month high of $6.30.

Cerus Corporation (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The firm had revenue of $9.53 million during the quarter, compared to analyst estimates of $9.14 million. During the same quarter in the prior year, the business posted ($0.18) earnings per share. Cerus Corporation’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities research analysts anticipate that Cerus Corporation will post ($0.68) earnings per share for the current fiscal year.

Several brokerages have recently commented on CERS. ValuEngine lowered Cerus Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub downgraded Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Zacks Investment Research raised Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $7.00 price objective on shares of Cerus Corporation in a report on Wednesday, June 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $7.25.

Cerus Corporation Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Institutional Ownership by Quarter for Cerus Corporation (NASDAQ:CERS)

Receive News & Stock Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related stocks with our FREE daily email newsletter.